VIRGINIA RETIREMENT SYSTEMS ET Al Acquires Shares of 54,103 10x Genomics $TXG

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of 10x Genomics (NASDAQ:TXG) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 54,103 shares of the company’s stock, valued at approximately $627,000.

A number of other institutional investors have also added to or reduced their stakes in TXG. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in 10x Genomics by 235.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after buying an additional 4,987,195 shares in the last quarter. Millennium Management LLC grew its holdings in 10x Genomics by 434.5% during the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock valued at $46,946,000 after buying an additional 4,371,327 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in 10x Genomics by 3,619.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock valued at $10,185,000 after buying an additional 1,135,356 shares in the last quarter. Iron Triangle Partners LP purchased a new stake in 10x Genomics during the 1st quarter valued at approximately $8,730,000. Finally, ARK Investment Management LLC grew its holdings in 10x Genomics by 7.5% during the 1st quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company’s stock valued at $112,143,000 after buying an additional 901,656 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on TXG. Wall Street Zen raised shares of 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Canaccord Genuity Group set a $16.00 price objective on shares of 10x Genomics in a report on Monday, August 11th. UBS Group increased their target price on 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the company a “hold” rating in a research report on Friday, August 8th. Finally, Morgan Stanley lowered their target price on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, 10x Genomics currently has an average rating of “Hold” and an average price target of $13.65.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares in the company, valued at $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the sale, the chief executive officer owned 945,892 shares of the company’s stock, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,149 shares of company stock worth $539,865 over the last three months. 9.39% of the stock is owned by insiders.

10x Genomics Stock Up 3.1%

Shares of TXG opened at $13.77 on Friday. The company has a market cap of $1.71 billion, a PE ratio of -19.67 and a beta of 2.05. The business has a fifty day moving average of $12.87 and a 200 day moving average of $11.33. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $18.21.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.10x Genomics’s revenue was up 12.9% on a year-over-year basis. During the same period last year, the company earned ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, research analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.